Literature DB >> 24687828

Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden.

Hanna Eriksson1, Johan Lyth, Eva Månsson-Brahme, Margareta Frohm-Nilsson, Christian Ingvar, Christer Lindholm, Peter Naredi, Ulrika Stierner, John Carstensen, Johan Hansson.   

Abstract

PURPOSE: To investigate the association between cohabitation status, clinical stage at diagnosis, and disease-specific survival in cutaneous malignant melanoma (CMM).
METHODS: This nationwide population-based study included 27,235 patients from the Swedish Melanoma Register diagnosed with a primary invasive CMM between 1990 and 2007 and linked data to nationwide, population-based registers followed up through 2012.
RESULTS: After adjustment for age at diagnosis, level of education, living area, period of diagnosis, and tumor site, the odds ratios (ORs) of higher stage at diagnosis were significantly increased among men living alone versus men living with a partner (stage II v stage I: OR, 1.42; 95% CI, 1.29 to 1.57; stage III or IV v stage I: OR, 1.43; 95% CI, 1.14 to 1.79). The OR for stage II versus stage I disease was also increased among women living alone (OR, 1.15; 95% CI, 1.04 to 1.28). After adjustments for the factors listed earlier, the CMM-specific survival was significantly decreased among men living alone (hazard ratio [HR] for death, 1.48; 95% CI, 1.33 to 1.65; P < .001). After additional adjustments for all potential and established prognostic factors, CMM-specific survival among men living alone versus men living with a partner remained significantly decreased (HR, 1.31; 95% CI, 1.18 to 1.46; P < .001), suggesting a residual adverse effect on survival not accounted for by these parameters.
CONCLUSION: In all age groups among men, living alone is significantly associated with reduced CMM-specific survival, partially attributed to a more advanced stage at diagnosis. This emphasizes the need for improved prevention and early detection strategies for this group.

Entities:  

Mesh:

Year:  2014        PMID: 24687828     DOI: 10.1200/JCO.2013.52.7564

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment.

Authors:  Mohammad A Obeid; Alaa A A Aljabali; Meriem Rezigue; Haneen Amawi; Hanin Alyamani; Shatha N Abdeljaber; Valerie A Ferro
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.

Authors:  Aljosja Rogiers; Joost J van den Oord; Marjan Garmyn; Marguerite Stas; Cindy Kenis; Hans Wildiers; Jean-Christophe Marine; Pascal Wolter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

Review 3.  Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

Authors:  Hildur Helgadottir; Iara Rocha Trocoli Drakensjö; Ada Girnita
Journal:  Front Oncol       Date:  2018-06-12       Impact factor: 6.244

4.  Contribution of insurance status to the association between marital status and cancer-specific survival: a mediation analysis.

Authors:  Kai-Bin Yang; Yuan-Zhe Zhang; Zi-Hang Chen; Chen-Fei Wu; Wei-Hong Zheng; Jia Kou; Wei Chen; Jin-Wei Chen; Si-Fan Qi; Qing Liu; Ying Sun; Jun Ma; Li Lin
Journal:  BMJ Open       Date:  2022-09-21       Impact factor: 3.006

5.  Trends in cutaneous melanoma mortality in Italy from 1982 to 2016.

Authors:  Giulia Briatico; Pamela Mancuso; Giuseppe Argenziano; Caterina Longo; Lucia Mangone; Elvira Moscarella; Gabriella Brancaccio; Riccardo Pampena
Journal:  Int J Dermatol       Date:  2022-04-01       Impact factor: 3.204

6.  Marital Status and Survival in Patients Diagnosed with Melanoma.

Authors:  J A Maas; A J Monreal; E L Diaz; G Castro; P Rodriguez de la Vega; M Varella
Journal:  Dermatol Res Pract       Date:  2020-01-30

7.  Influence of socioeconomic factors and region of residence on cancer stage of malignant melanoma: a Danish nationwide population-based study.

Authors:  Else Helene Ibfelt; Marianne Steding-Jessen; Susanne Oksbjerg Dalton; Sanne Lykke Lundstrøm; Merete Osler; Lisbet Rosenkrantz Hölmich
Journal:  Clin Epidemiol       Date:  2018-07-10       Impact factor: 4.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.